Kris Vaddi

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

CCR2 modulates inflammatory and metabolic effects of high-fat feeding

Stuart P. Weisberg, Deborah Hunter, Reid Huber et al. · Journal of Clinical Investigation · 2005 · 1.5K citations · Full text

Life Sciences, Molecular Biology, Physiology +17

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

Srđan Verstovšek, Hagop M. Kantarjian, Ruben A. Mesa et al. · New England Journal of Medicine · 2010 · 1.2K citations · Full text

Medicine, Hematology, Pharmacology +13

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Alfonso Quintás‐Cardama, Kris Vaddi, Phillip Liu et al. · Blood · 2010 · 827 citations

Medicine, Hematology, Pharmacology +11

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

Jordan S. Fridman, Peggy Scherle, Robert J. Collins et al. · The Journal of Immunology · 2010 · 463 citations · Full text

Medicine, Immunology, Pharmacology +17